Mobilewalla, Inc., In the Matter of
Announcing settlement with Mobilewalla for collecting selling sensitive location data.
Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding.
Announcing settlement with Mobilewalla for collecting selling sensitive location data.
Announcing settlement with IntelliVision Technologies over allegations that the company made false claims about its AI-powered facial recognition software.
In December 2024, the FTC announced a court order requiring GOAT, a leading online marketplace for sneakers, apparel, and accessories, to pay more than $2 million for violating an agency rule requiring companies to have reasonable shipping practices.
As a result of a Federal Trade Commission lawsuit, a federal court has temporarily shut down the operations of a business opportunity scam that has taken more than $12 million from consumers with false promises of big returns selling goods through Amazon and Walmart.
According to a complaint filed by the FTC, since at least 2022, the scheme operated under the names Lunar Capital Ventures, Ecom Genie and Profitable Automation, and before that as the now-dissolved company Valiant Consultants Inc. Under each of these names, the scheme has made enticing but bogus claims that consumers could earn lavish profits by paying tens of thousands of dollars to start online e-commerce businesses. The promised earnings rarely, if ever, materialize, and most consumers lose substantial amounts of money.
Announcing settlement Evolv Technologies over allegations that the company made false claims about its AI-powered security screening system
The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.